Corticosteroids for community-acquired pneumonia

Time to act!

Djillali Annane, Gianfranco Meduri

Research output: Contribution to journalComment/debate

10 Citations (Scopus)

Abstract

The use of corticosteroids for the treatment of community-acquired pneumonia has been reported for almost 50 years. A recent systematic analysis of the relevant literature suggested that corticosteroids reduce the critical illness associated with community-acquired pneumonia. There is little doubt that a prolonged administration of a moderate dose of corticosteroids may alleviate the systemic inflammatory response and subsequent organ dysfunction in severe infection. Whether these favorable effects on morbidity may translate into better survival and quality of life needs to be addressed in additional adequately powered randomized controlled trials.

Original languageEnglish (US)
Article number166
JournalCritical Care
Volume12
Issue number4
DOIs
StatePublished - Jul 14 2008

Fingerprint

Pneumonia
Adrenal Cortex Hormones
Critical Illness
Randomized Controlled Trials
Quality of Life
Morbidity
Infection

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Corticosteroids for community-acquired pneumonia : Time to act! / Annane, Djillali; Meduri, Gianfranco.

In: Critical Care, Vol. 12, No. 4, 166, 14.07.2008.

Research output: Contribution to journalComment/debate

@article{2c23b9f261f44de2b33c0bcedcde8e06,
title = "Corticosteroids for community-acquired pneumonia: Time to act!",
abstract = "The use of corticosteroids for the treatment of community-acquired pneumonia has been reported for almost 50 years. A recent systematic analysis of the relevant literature suggested that corticosteroids reduce the critical illness associated with community-acquired pneumonia. There is little doubt that a prolonged administration of a moderate dose of corticosteroids may alleviate the systemic inflammatory response and subsequent organ dysfunction in severe infection. Whether these favorable effects on morbidity may translate into better survival and quality of life needs to be addressed in additional adequately powered randomized controlled trials.",
author = "Djillali Annane and Gianfranco Meduri",
year = "2008",
month = "7",
day = "14",
doi = "10.1186/cc6940",
language = "English (US)",
volume = "12",
journal = "Critical Care",
issn = "1466-609X",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Corticosteroids for community-acquired pneumonia

T2 - Time to act!

AU - Annane, Djillali

AU - Meduri, Gianfranco

PY - 2008/7/14

Y1 - 2008/7/14

N2 - The use of corticosteroids for the treatment of community-acquired pneumonia has been reported for almost 50 years. A recent systematic analysis of the relevant literature suggested that corticosteroids reduce the critical illness associated with community-acquired pneumonia. There is little doubt that a prolonged administration of a moderate dose of corticosteroids may alleviate the systemic inflammatory response and subsequent organ dysfunction in severe infection. Whether these favorable effects on morbidity may translate into better survival and quality of life needs to be addressed in additional adequately powered randomized controlled trials.

AB - The use of corticosteroids for the treatment of community-acquired pneumonia has been reported for almost 50 years. A recent systematic analysis of the relevant literature suggested that corticosteroids reduce the critical illness associated with community-acquired pneumonia. There is little doubt that a prolonged administration of a moderate dose of corticosteroids may alleviate the systemic inflammatory response and subsequent organ dysfunction in severe infection. Whether these favorable effects on morbidity may translate into better survival and quality of life needs to be addressed in additional adequately powered randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=65849113468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65849113468&partnerID=8YFLogxK

U2 - 10.1186/cc6940

DO - 10.1186/cc6940

M3 - Comment/debate

VL - 12

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 4

M1 - 166

ER -